AptarGroup, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Unaudited results cover the three months ended March 31, 2023, compared with the same quarter of 2022. AptarGroup makes drug-delivery, dispensing, closure and related packaging solutions. Effective January 1, 2023, it reorganized reporting into Aptar Pharma, Aptar Beauty and Aptar Closures; prior-period segment data was recast.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Net sales | $860.1 million | $844.9 million |
| Operating income / margin | $83.9 million / 9.8% | $97.7 million / 11.6% |
| Net income attributable to AptarGroup | $54.8 million | $62.4 million |
| Diluted EPS | $0.82 | $0.93 |
| Adjusted EBITDA / margin | $153.7 million / 17.9% | $156.3 million / 18.5% |
| Cash from operations | $98.3 million | $92.1 million |
| Free cash flow | $20.5 million | $27.0 million |
At March 31, 2023, cash and equivalents were $126.8 million, total debt was $1.187 billion and net debt was $1.061 billion. Net debt to net capital was 33.3%, unchanged from year-end 2022. Current assets were $1.482 billion and current liabilities were $1.041 billion. The $600 million revolving credit facility was undrawn; leverage and interest coverage ratios were 1.80x and 14.19x, respectively, against covenant limits of 3.50x maximum and 3.00x minimum.
Material changes versus prior period
- Reported sales increased 2%; management-reported core sales, excluding currency and acquisitions, grew 4%. Approximately half of core growth came from inflation-related pricing and half from higher volumes and product mix. Currency translation reduced sales growth by about 2%.
- Operating income fell about 14% and diluted EPS declined from $0.93 to $0.82. Operating margin contracted 1.8 percentage points, primarily reflecting $11.5 million of restructuring expense and operating pressures in Pharma.
- Pharma sales grew 4%, but segment Adjusted EBITDA fell 5% to $109.3 million and margin declined to 30.7% from 33.7%. Beauty sales rose 6% and Adjusted EBITDA rose 8% to $37.2 million. Closures sales declined 8%, while Adjusted EBITDA increased 8% to $26.0 million.
- Operating cash flow improved by $6.2 million, but free cash flow decreased as capital expenditures rose to $77.8 million from $73.1 million and there were no government grant proceeds, compared with $8.0 million in Q1 2022.
Outlook, commentary, risks and unusual items
- For Q2 2023, management expects proprietary Pharma dispensing devices and Beauty to grow, injectables revenue to ramp up after ERP implementation, and gradual improvement in Closures as customers reduce inventories. EPS guidance is $1.11–$1.19, excluding restructuring, changes in fair value of equity investments and acquisition costs; assumed effective tax rate is 26%–28%. No full-year EPS guidance is provided in the filing.
- Management estimates 2023 capital expenditures, net of government grants, of approximately $280–$300 million. It cites a strong financial position and expects operating cash generation and available credit to support requirements.
- The injectables division had approximately 15% fewer shipping days due to the ERP cutover; lower capacity utilization and start-up costs also pressured margins. ERP implementation and capacity expansion contributed to higher cost of sales.
- The $11.5 million Q1 restructuring charge relates to an optimization initiative begun in 2022; cumulative expense was $17.8 million at quarter-end. The quarter also included $0.3 million of acquisition-related costs and a $0.2 million net investment gain.
- Q1 acquisitions included iD SCENT and an 80% interest in Gulf Closures, funded with cash; their consolidated impact was not significant. The $25.3 million Fusion contingent consideration liability was repaid after March 31.
- Customs-duty claims total approximately $13 million in principal plus $5–$6 million in interest and penalties; no liability was recorded because the outcome and amount remain uncertain. The filing also notes ordinary-course litigation and an insurance recovery lawsuit; no gain was recognized for the latter.
- Key stated risks include weaker demand or recession, inflation and input-cost changes, supply constraints, labor availability, foreign-exchange movements, higher interest rates, customer concentration or losses, ERP and facility-project execution, cybersecurity, and legal or regulatory outcomes.
Important facts for investors to verify
- Whether Pharma injectables operations recover as planned after the ERP cutover, and whether prescription and consumer-health growth offsets weaker injectables and active-material-science demand.
- Whether Closures volumes and customer inventory levels improve, and how lower resin-cost pass-throughs affect sales and margins.
- Progress, remaining costs and expected benefits of the optimization initiative, alongside the timing and cost of ERP and capacity investments.
- Execution of Q2 EPS guidance and the $280–$300 million capital-spending estimate; monitor operating cash flow, free cash flow and working capital.
- Debt maturities, including approximately $215.6 million due within one year, covenant headroom, and the impact of interest rates and currency movements.
- Resolution of the customs-duty claims and other contingencies, and any remaining acquisition or integration obligations.